{"doi":"10.3390/pharmaceutics12060545","title":"Development of Antibody–Oligonucleotide Complexes for Targeting Exosomal MicroRNA","abstract":"<jats:p>MicroRNAs in exosomes (exosomal miRNAs) are considered as significant targets for cancer therapy. Anti-miR oligonucleotides are often used for the functional inhibition of miRNAs; however, there are no studies regarding the regulation of exosomal miRNA functions. In this study, we attempted to develop a novel drug delivery system using anti-exosome antibody–anti-miR oligonucleotide complexes (ExomiR-Tracker) to hijack exosomes to carry anti-miR oligonucleotides inside exosome-recipient cells. We found that ExomiR-Tracker bound to the exosomes, and then the complexes were introduced into the recipient cells. We also found that anti-miR oligonucleotides introduced into the recipient cells can exhibit inhibitory effects on exosomal miRNA functions in vitro and in vivo. We believe that our strategy would be a promising one for targeting exosomal miRNAs.</jats:p>","journal":"Pharmaceutics","year":2020,"id":663234,"datarank":0.4636563680037475,"base_score":3.091042453358316,"endowment":3.091042453358316,"self_citation_contribution":0.4636563680037475,"citation_network_contribution":0.0,"self_endowment_contribution":0.4636563680037475,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":21,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1731501,"name":"Shota Oyama","orcid":null,"position":1,"is_corresponding":false},{"id":1731502,"name":"Yusuke Kishimoto","orcid":null,"position":2,"is_corresponding":false},{"id":1731503,"name":"Ryo Konishi","orcid":null,"position":3,"is_corresponding":false},{"id":1521609,"name":"Tsuyoshi Yamamoto","orcid":"0000-0002-3206-2455","position":4,"is_corresponding":false},{"id":1731504,"name":"Akio Kobori","orcid":null,"position":5,"is_corresponding":false},{"id":1731505,"name":"Hiroshi Harada","orcid":null,"position":6,"is_corresponding":false},{"id":755359,"name":"Eishi Ashihara","orcid":null,"position":7,"is_corresponding":false},{"id":559577,"name":"Hiroshi Sugiyama","orcid":"0000-0001-8923-5946","position":8,"is_corresponding":false},{"id":615984,"name":"Akira Murakami","orcid":"0000-0002-0022-2514","position":9,"is_corresponding":false},{"id":1731500,"name":"Asako Yamayoshi","orcid":"0000-0002-7527-4255","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Development of Antibody–Oligonucleotide Complexes for Targeting Exosomal MicroRNA","abstract":"<jats:p>MicroRNAs in exosomes (exosomal miRNAs) are considered as significant targets for cancer therapy. Anti-miR oligonucleotides are often used for the functional inhibition of miRNAs; however, there are no studies regarding the regulation of exosomal miRNA functions. In this study, we attempted to develop a novel drug delivery system using anti-exosome antibody–anti-miR oligonucleotide complexes (ExomiR-Tracker) to hijack exosomes to carry anti-miR oligonucleotides inside exosome-recipient cells. We found that ExomiR-Tracker bound to the exosomes, and then the complexes were introduced into the recipient cells. We also found that anti-miR oligonucleotides introduced into the recipient cells can exhibit inhibitory effects on exosomal miRNA functions in vitro and in vivo. We believe that our strategy would be a promising one for targeting exosomal miRNAs.</jats:p>","is_dataset_classified":null,"base_score":3.091042453358316,"endowment":3.091042453358316,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32545479","pmcid":"PMC7355672","openalex_id":"https://openalex.org/W3034520772","authors":[],"funders":[{"funder_name":"Japan Science and Technology Agency","grant_id":"JPMJPR178A","title":null},{"funder_name":"Ministry of Education, Culture, Sports, Science and Technology","grant_id":"18H02087","title":null},{"funder_name":"Network Joint Research Center for Materials and Devices","grant_id":"20194040 AY","title":null}],"total_grants":3,"fwci":1.1943,"citation_percentile":0.77688617,"influential_citations":0,"citation_trend":[{"year":2020,"count":1},{"year":2021,"count":5},{"year":2022,"count":5},{"year":2023,"count":5},{"year":2024,"count":3},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/1999-4923/12/6/545/pdf","host_type":"journal"},{"url":"https://www.mdpi.com/1999-4923/12/6/545/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/pharmaceutics12060545","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32545479","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7355672","host_type":"repository"},{"url":"https://doaj.org/article/85c5db2e98b2488b90f9b8ff758266e1","host_type":"repository"},{"url":"https://nagasaki-u.repo.nii.ac.jp/records/966","host_type":"repository"},{"url":"http://dx.doi.org/10.3390/pharmaceutics12060545","host_type":"repository"},{"url":"http://hdl.handle.net/10069/40162","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7355672","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7355672?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Extracellular vesicles in disease","MicroRNA in disease regulation","RNA Interference and Gene Delivery"],"mesh_terms":[],"keywords":["Microvesicles","Exosome","microRNA","Oligonucleotide","In vivo","Cell biology","In vitro","Biology","Computational biology","Cancer research","Chemistry","Gene","Biochemistry","Genetics","Antibody","Drug delivery system","Nucleic Acid Drug"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T20:32:06.666869Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}